Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on RVNC. HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Finally, William Blair reaffirmed a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.66.

Revance Therapeutics Stock Down 6.0 %

Shares of NASDAQ:RVNC opened at $3.78 on Tuesday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The stock’s 50 day moving average is $5.01 and its 200-day moving average is $4.43. The firm has a market capitalization of $396.52 million, a price-to-earnings ratio of -1.96 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. Equities research analysts anticipate that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

Several large investors have recently modified their holdings of RVNC. Vanguard Group Inc. raised its position in Revance Therapeutics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock valued at $26,560,000 after purchasing an additional 328,781 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Revance Therapeutics by 28.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 15,496 shares in the last quarter. California State Teachers Retirement System increased its position in Revance Therapeutics by 9.8% during the 1st quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 8,668 shares during the period. Opaleye Management Inc. bought a new position in Revance Therapeutics in the 1st quarter worth $3,862,000. Finally, DNB Asset Management AS lifted its position in shares of Revance Therapeutics by 25.4% in the 2nd quarter. DNB Asset Management AS now owns 60,229 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 12,201 shares during the period. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.